Key Insights

Highlights

Success Rate

93% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

5.3%

1 terminated out of 19 trials

Success Rate

92.9%

+6.4% vs benchmark

Late-Stage Pipeline

16%

3 trials in Phase 3/4

Results Transparency

23%

3 of 13 completed with results

Key Signals

3 with results93% success

Data Visualizations

Phase Distribution

14Total
Not Applicable (6)
P 1 (1)
P 2 (4)
P 4 (3)

Trial Status

Completed13
Unknown3
Recruiting2
Terminated1

Trial Success Rate

92.9%

Benchmark: 86.5%

Based on 13 completed trials

Clinical Trials (19)

Showing 19 of 19 trials
NCT06939088Phase 2Recruiting

Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder

NCT06872463RecruitingPrimary

Karolinska Schizophrenia Project

NCT03309475Not ApplicableCompletedPrimary

Effectiveness of a Mindfulness-based Group Training Addressing Social Cognition in First Episode Psychosis (AGES-Mind)

NCT03133143Not ApplicableCompleted

Video Games Among People With Schizophrenia

NCT00363181Completed

Side Effects of Antipsychotic Medications

NCT00748566Phase 4TerminatedPrimary

One-Year Trial Of Oral Ziprasidone In Patients With Metabolic Syndrome

NCT02308462Not ApplicableCompletedPrimary

Implementation and Evaluation of a Family-based Intervention Program for Children of Mentally Ill Parents

NCT02928965Phase 2CompletedPrimary

The Benefit of Minocycline on Negative Symptoms in Schizophrenia: Extent and Mechanisms

NCT02307396Phase 4Completed

Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients

NCT00137189Not ApplicableCompleted

Resource-oriented Music Therapy for Psychiatric Patients With Low Therapy Motivation

NCT02321943CompletedPrimary

Anomalous Self-Experience in First Episode Psychosis - A Six-Year Follow-Up Study

NCT02240173Phase 1UnknownPrimary

Antipsychotic Effects of Sorghum Bicolor (JOBELYN) in the Treatment of Schizophrenia

NCT00309452Not ApplicableCompletedPrimary

Specialized Treatment Early in Psychosis (STEP)

NCT00218218Phase 2CompletedPrimary

Effects of Transdermal Nicotine on Smoking, Craving and Withdrawal in People With Schizophrenia

NCT00135772CompletedPrimary

Nicotine and Cotinine Levels in Smokers With Schizophrenia and Schizoaffective Disorder - 2

NCT00136760Phase 2CompletedPrimary

Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia

NCT01968161Phase 4UnknownPrimary

Investigator Initiated Study - Asenapine Early Psychosis

NCT01196858CompletedPrimary

Duration of Untreated Psychosis (DUP) and Pathways to Care in Nordland

NCT00791882Not ApplicableUnknownPrimary

Social Skills Training in Refractory Schizophrenia

Showing all 19 trials

Research Network

Activity Timeline